Premiere Biomedical Inc. (OTCQB:BIEI) is a research-based company that focuses on discovering and developing medical treatments for humans targeting the treatment of Alzheimer’s Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. On June 7, 2013, BIEI entered a Cooperative Research and Development Agreement (“CRADA”) with the Clinical Investigation Regulatory Office U.S. Army Medical Research and Material Command (“CIRO”) focusing on the prevention of suicidal ideation and clinical depression, and to assist in the antibody creation that decreases neuropathology findings in traumatic brain injury. BIEI will provide the basis for the study and cover approximately $10,000 in costs. For more information, read here: https://www.sec.gov/…/1515740/0001477932160...iei_s1.htm
Uptick Newswire provided the above as a paid service. It is understood that investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence. We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.